Ford, Ian

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study

Ford, I., Murray, H., McCowan, C., & Packard, C. J. (2016) · Circulation

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 238

Glycated hemoglobin measurement and prediction of cardiovascular disease

Di Angelantonio, E., Gao, P., Khan, H., Butterworth, A. S., Wormser, D., Kaptoge, S., Kondapally Seshasai, S. R., Thompson, A., Sarwar, N., Willeit, P., et al. (2014) · JAMA

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 231

Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk

Nanchen, D., Gussekloo, J., Westendorp, R. G. J., Stott, D. J., Jukema, J. W., Trompet, S., Ford, I., Welsh, P., Sattar, N., Macfarlane, P. W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsHeart Failure Treatment and Management

Cited by 211

Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation

Sinner, M. F., Tucker, N. R., Lunetta, K. L., Ozaki, K., Smith, J. G., Trompet, S., Bis, J. C., Lin, H., Chung, M. K., Nielsen, J. B., et al. (2014) · Circulation

Cardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and Outcomes

Cited by 205

Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review

Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment

Statistical Methods in Clinical TrialsMeta-analysis and systematic reviews

Cited by 194

Socio-economic status is associated with epigenetic differences in the pSoBid cohort

McGuinness, D., McGlynn, L. M., Johnson, P. C., MacIntyre, A., Batty, G. D., Burns, H., Cavanagh, J., Deans, K. A., Ford, I., McConnachie, A., et al. (2012) · International Journal of Epidemiology

Epigenetics and DNA MethylationHealth disparities and outcomes

Cited by 193

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J., Ford, I., & Ray, K. K. (2017) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 185

Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis

Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA

Pancreatitis Pathology and TreatmentLipoproteins and Cardiovascular Health

Cited by 181

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity

Joshi, P. K., Pirastu, N., Kentistou, K. A., Fischer, K., Hofer, E., Schraut, K. E., Clark, D. W., Nutile, T., Barnes, C. L. K., Timmers, P. R. H. J., et al. (2017) · Nature Communications

Genetic Associations and EpidemiologyGenetics, Aging, and Longevity in Model Organisms

Cited by 161

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 160

Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese

Lubitz, S. A., Lunetta, K. L., Lin, H., Arking, D. E., Trompet, S., Li, G., Krijthe, B. P., Chasman, D. I., Barnard, J., Kleber, M. E., et al. (2014) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesGenetic Associations and Epidemiology

Cited by 148

GWAS for executive function and processing speed suggests involvement of the CADM2 gene

Ibrahim-Verbaas, C. A., Bressler, J., Debette, S., Schuur, M., Smith, A. V., Bis, J. C., Davies, G., Trompet, S., Smith, J. A., Wolf, C., et al. (2016) · Molecular Psychiatry

Genetic Associations and EpidemiologyCognitive Abilities and Testing

Cited by 147

Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort

Shiels, P. G., McGlynn, L. M., MacIntyre, A., Johnson, P. C. D., Batty, G. D., Burns, H., Cavanagh, J., Deans, K. A., Ford, I., McConnachie, A., et al. (2011) · PLoS ONE

Telomeres, Telomerase, and SenescenceHealth disparities and outcomes

Cited by 143

Unraveling the directional link between adiposity and inflammation: A bidirectional Mendelian randomization approach

Welsh, P., Polisecki, E., Robertson, M., Jahn, S., Buckley, B. M., de Craen, A. J. M., Ford, I., Jukema, J. W., Macfarlane, P. W., Packard, C. J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism

Adipokines, Inflammation, and Metabolic DiseasesGenetic Associations and Epidemiology

Cited by 140

The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial

Leslie, W. S., Ford, I., Sattar, N., Hollingsworth, K. G., Adamson, A., Sniehotta, F. F., McCombie, L., Brosnahan, N., Ross, H., Mathers, J. C., et al. (2016) · BMC Family Practice

Diabetes Treatment and ManagementBariatric Surgery and Outcomes

Cited by 132

Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study

Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsLiver Disease Diagnosis and Treatment

Cited by 127

Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism

Mooijaart, S. P., Du Puy, R. S., Stott, D. J., Kearney, P. M., Rodondi, N., Westendorp, R. G. J., den Elzen, W. P. J., Postmus, I., Poortvliet, R. K. E., van Heemst, D., et al. (2019) · JAMA

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 121

Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 121

Effect of pravastatin on cerebral infarcts and white matter lesions

ten Dam, V. H., van den Heuvel, D. M. J., van Buchem, M. A., Westendorp, R. G. J., Bollen, E. L. E. M., Ford, I., de Craen, A. J. M., & Blauw, G. J. (2005) · Neurology

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 113

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 109

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 104

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., et al. (2010) · Circulation

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 104

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

MacDonald, T. M., Ford, I., Nuki, G., Mackenzie, I. S., De Caterina, R., Findlay, E., Hallas, J., Hawkey, C. J., Ralston, S., Walters, M., et al. (2014) · BMJ Open

Gout, Hyperuricemia, Uric AcidDrug-Induced Adverse Reactions

Cited by 93